Nifty
:
18616.50
Sensex
:
62997.66
17.85 (0.10%)
151.28 (0.24%)
Nifty
Sensex
:
:
18616.50
62997.66
17.85 (0.10%)
151.28 (0.24%)

Ipca Laboratories Ltd.

Pharmaceuticals & Drugs - Global

Rating :
44/99

BSE: 524494 | NSE: IPCALAB

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 17,478.95
  • 37.09
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 17,629.53
  • 0.58%
  • 2.97

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.29%
  • 0.44%
  • 7.25%
  • FII
  • DII
  • Others
  • 10.58%
  • 33.87%
  • 1.57%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.53
  • 12.22
  • 7.86

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.87
  • 23.26
  • 7.15

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.81
  • 30.02
  • 13.81

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 33.95
  • 30.80
  • 28.42

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.13
  • 4.65
  • 5.06

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.06
  • 19.00
  • 18.73

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Net Sales
1,511.63
1,289.10
17.26%
1,546.00
1,430.47
8.08%
1,600.95
1,544.43
3.66%
1,585.74
1,565.79
1.27%
Expenses
1,330.59
1,069.77
24.38%
1,330.14
1,122.66
18.48%
1,340.31
1,178.85
13.70%
1,316.51
1,149.25
14.55%
EBITDA
181.04
219.33
-17.46%
215.86
307.81
-29.87%
260.64
365.58
-28.71%
269.23
416.54
-35.37%
EBIDTM
11.98%
17.01%
13.96%
21.52%
16.28%
23.67%
16.98%
26.60%
Other Income
36.39
14.54
150.28%
30.89
12.93
138.90%
36.23
18.08
100.39%
22.11
21.02
5.19%
Interest
18.45
3.38
445.86%
10.84
1.43
658.04%
9.31
1.06
778.30%
6.94
1.82
281.32%
Depreciation
69.54
60.94
14.11%
66.57
58.65
13.50%
63.74
56.96
11.90%
61.71
55.87
10.45%
PBT
129.44
169.55
-23.66%
169.34
260.66
-35.03%
223.82
325.64
-31.27%
222.69
379.87
-41.38%
Tax
48.37
28.76
68.18%
53.73
57.33
-6.28%
77.00
67.91
13.39%
74.26
70.77
4.93%
PAT
81.07
140.79
-42.42%
115.61
203.33
-43.14%
146.82
257.73
-43.03%
148.43
309.10
-51.98%
PATM
5.36%
10.92%
7.48%
14.21%
9.17%
16.69%
9.36%
19.74%
EPS
3.02
5.13
-41.13%
4.25
3.88
9.54%
5.67
9.86
-42.49%
5.64
12.09
-53.35%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
6,244.32
5,796.74
5,394.94
4,619.03
3,745.69
3,257.76
3,156.19
2,867.11
3,144.40
3,281.77
2,805.94
Net Sales Growth
7.11%
7.45%
16.80%
23.32%
14.98%
3.22%
10.08%
-8.82%
-4.19%
16.96%
 
Cost Of Goods Sold
2,306.51
1,790.78
1,547.98
1,455.41
1,090.34
978.34
939.40
903.04
968.00
963.06
955.10
Gross Profit
3,937.81
4,005.96
3,846.96
3,163.62
2,655.35
2,279.42
2,216.79
1,964.07
2,176.40
2,318.71
1,850.84
GP Margin
63.06%
69.11%
71.31%
68.49%
70.89%
69.97%
70.24%
68.50%
69.22%
70.65%
65.96%
Total Expenditure
5,317.55
4,539.12
3,913.71
3,728.56
3,067.42
2,815.78
2,740.77
2,593.42
2,630.33
2,569.79
2,268.34
Power & Fuel Cost
-
242.12
207.10
201.22
176.50
161.92
151.00
141.67
135.94
127.91
104.79
% Of Sales
-
4.18%
3.84%
4.36%
4.71%
4.97%
4.78%
4.94%
4.32%
3.90%
3.73%
Employee Cost
-
1,177.39
1,013.57
921.23
787.40
735.88
695.98
625.58
566.70
497.99
391.79
% Of Sales
-
20.31%
18.79%
19.94%
21.02%
22.59%
22.05%
21.82%
18.02%
15.17%
13.96%
Manufacturing Exp.
-
610.04
524.21
471.80
374.26
366.92
404.52
387.75
439.11
415.69
331.73
% Of Sales
-
10.52%
9.72%
10.21%
9.99%
11.26%
12.82%
13.52%
13.96%
12.67%
11.82%
General & Admin Exp.
-
261.34
242.22
249.90
271.85
268.52
246.68
245.42
246.73
255.40
205.02
% Of Sales
-
4.51%
4.49%
5.41%
7.26%
8.24%
7.82%
8.56%
7.85%
7.78%
7.31%
Selling & Distn. Exp.
-
402.81
324.86
359.15
317.84
277.62
280.74
223.67
245.00
231.18
212.94
% Of Sales
-
6.95%
6.02%
7.78%
8.49%
8.52%
8.89%
7.80%
7.79%
7.04%
7.59%
Miscellaneous Exp.
-
54.64
53.77
69.85
49.23
26.58
22.45
66.29
28.85
78.56
212.94
% Of Sales
-
0.94%
1.00%
1.51%
1.31%
0.82%
0.71%
2.31%
0.92%
2.39%
2.39%
EBITDA
926.77
1,257.62
1,481.23
890.47
678.27
441.98
415.42
273.69
514.07
711.98
537.60
EBITDA Margin
14.84%
21.70%
27.46%
19.28%
18.11%
13.57%
13.16%
9.55%
16.35%
21.69%
19.16%
Other Income
125.62
121.72
129.19
86.50
74.66
58.08
54.76
40.77
58.69
51.97
39.88
Interest
45.54
11.20
12.27
19.77
22.24
27.57
26.91
34.56
32.13
30.23
36.48
Depreciation
261.56
232.42
209.17
210.50
182.42
177.73
172.95
163.26
179.55
103.13
86.73
PBT
745.29
1,135.72
1,388.98
746.70
548.27
294.76
270.32
116.64
361.08
630.59
454.27
Tax
253.36
224.77
240.14
135.33
104.24
51.11
67.52
20.44
101.93
152.39
129.94
Tax Rate
33.99%
19.79%
17.29%
18.12%
19.01%
17.34%
24.98%
17.52%
28.23%
24.17%
28.60%
PAT
491.93
905.24
1,147.71
614.13
447.39
243.65
202.80
96.20
259.15
478.20
324.33
PAT before Minority Interest
484.26
910.95
1,148.84
611.37
444.03
243.65
202.80
96.20
259.15
478.20
324.33
Minority Interest
-7.67
-5.71
-1.13
2.76
3.36
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
7.88%
15.62%
21.27%
13.30%
11.94%
7.48%
6.43%
3.36%
8.24%
14.57%
11.56%
PAT Growth
-46.00%
-21.13%
86.88%
37.27%
83.62%
20.14%
110.81%
-62.88%
-45.81%
47.44%
 
EPS
19.39
35.68
45.24
24.21
17.63
9.60
7.99
3.79
10.21
18.85
12.78

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
5,491.97
4,701.65
3,627.48
3,122.39
2,688.57
2,455.26
2,259.19
2,208.43
1,959.66
1,553.78
Share Capital
25.37
25.37
25.27
25.27
25.24
25.24
25.24
25.24
25.24
25.24
Total Reserves
5,466.60
4,676.28
3,590.27
3,097.12
2,663.01
2,430.02
2,233.95
2,183.19
1,934.42
1,528.54
Non-Current Liabilities
602.07
189.69
290.29
313.40
419.42
548.32
662.57
699.57
459.45
509.52
Secured Loans
395.18
9.13
88.80
133.94
234.01
347.22
433.63
447.65
292.12
366.21
Unsecured Loans
0.00
0.00
14.17
6.91
0.00
4.52
50.64
55.56
1.88
0.00
Long Term Provisions
42.73
38.56
32.23
25.28
25.88
24.55
20.22
18.03
14.93
12.21
Current Liabilities
1,465.88
1,160.54
1,326.42
1,097.50
1,007.57
955.93
969.95
904.36
791.45
633.65
Trade Payables
557.70
664.86
609.85
524.32
423.47
396.54
421.11
306.59
340.99
268.37
Other Current Liabilities
420.52
204.49
304.57
274.74
266.75
316.41
297.50
236.44
250.88
166.00
Short Term Borrowings
367.81
176.61
310.95
209.69
239.04
177.30
184.85
325.35
143.94
157.14
Short Term Provisions
119.85
114.58
101.05
88.75
78.31
65.68
66.49
35.98
55.64
42.14
Total Liabilities
7,636.84
6,066.41
5,257.82
4,548.83
4,115.56
3,959.51
3,891.71
3,812.36
3,210.56
2,696.95
Net Block
2,417.52
2,072.43
2,058.73
1,940.38
1,952.96
1,983.27
2,014.18
1,800.43
1,353.59
1,104.23
Gross Block
3,774.65
3,201.39
2,985.73
2,632.86
2,464.33
2,318.22
2,176.95
2,546.33
1,932.05
1,579.07
Accumulated Depreciation
1,341.29
1,128.96
927.00
692.48
511.37
334.95
162.77
745.90
578.46
474.84
Non Current Assets
3,179.67
2,629.45
2,402.11
2,171.08
2,170.08
2,217.69
2,269.79
2,198.38
1,609.14
1,299.78
Capital Work in Progress
306.43
234.82
133.28
66.33
73.00
94.64
128.74
267.22
164.90
129.17
Non Current Investment
269.88
111.43
71.31
30.05
17.52
22.24
25.82
16.19
9.00
8.87
Long Term Loans & Adv.
169.63
184.42
124.68
128.36
115.83
103.58
78.44
103.47
71.26
47.49
Other Non Current Assets
16.21
26.35
14.11
5.96
10.77
13.96
22.61
11.07
10.39
10.02
Current Assets
4,457.17
3,436.96
2,855.71
2,377.75
1,945.48
1,741.82
1,621.92
1,613.98
1,601.42
1,397.17
Current Investments
719.31
393.83
238.25
90.38
69.35
113.57
0.00
0.00
0.15
0.15
Inventories
1,857.97
1,594.81
1,323.12
1,072.50
880.59
882.22
837.42
926.56
847.58
741.03
Sundry Debtors
910.78
811.75
895.20
681.51
602.27
500.16
445.87
353.00
449.79
417.81
Cash & Bank
640.66
365.07
180.92
282.30
150.57
35.85
175.54
124.79
76.01
58.24
Other Current Assets
328.45
234.70
195.92
221.21
242.70
210.02
163.09
209.63
227.89
179.94
Short Term Loans & Adv.
201.80
36.80
22.30
29.85
14.44
15.56
17.31
36.19
53.84
31.22
Net Current Assets
2,991.29
2,276.42
1,529.29
1,280.25
937.91
785.89
651.97
709.62
809.97
763.52
Total Assets
7,636.84
6,066.41
5,257.82
4,548.83
4,115.56
3,959.51
3,891.71
3,812.36
3,210.56
2,696.95

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
856.04
1,090.13
570.35
501.03
341.13
281.91
708.65
455.29
522.29
388.77
PBT
1,135.72
1,388.98
738.89
546.46
290.53
262.06
116.64
361.08
630.59
454.27
Adjustment
195.11
183.07
247.37
187.36
192.51
174.86
211.11
187.91
139.92
126.16
Changes in Working Capital
-272.75
-236.33
-263.69
-121.97
-84.44
-103.73
410.30
-18.68
-117.72
-100.10
Cash after chg. in Working capital
1,058.08
1,335.72
722.57
611.85
398.60
333.19
738.05
530.31
652.79
480.33
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-202.04
-245.59
-152.22
-110.82
-57.47
-51.28
-29.40
-75.02
-130.50
-91.56
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-855.05
-520.69
-509.65
-165.06
-135.40
-148.82
-218.33
-676.40
-369.01
-259.87
Net Fixed Assets
-510.47
-307.20
-284.34
-46.98
-60.09
-105.61
466.60
-716.66
-362.17
-275.00
Net Investments
-579.68
-219.12
-326.48
-106.61
-4.05
-114.15
-15.57
-52.96
-6.96
20.86
Others
235.10
5.63
101.17
-11.47
-71.26
70.94
-669.36
93.22
0.12
-5.73
Cash from Financing Activity
426.81
-305.82
-136.54
-183.20
-130.41
-159.13
-461.51
250.54
-136.13
-82.93
Net Cash Inflow / Outflow
427.80
263.62
-75.84
152.77
75.32
-26.04
28.81
29.43
17.15
45.97
Opening Cash & Equivalents
559.01
295.39
370.92
218.15
142.83
168.87
140.06
74.25
56.69
10.72
Closing Cash & Equivalent
990.93
559.01
295.39
370.92
218.15
142.83
168.87
103.68
74.25
56.69

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
216.47
185.32
286.15
247.12
213.02
194.55
179.02
174.99
155.28
123.12
ROA
13.30%
20.29%
12.47%
10.25%
6.03%
5.17%
2.50%
7.38%
16.19%
12.91%
ROE
17.87%
27.63%
18.15%
15.28%
9.47%
8.60%
4.31%
12.43%
27.22%
23.10%
ROCE
20.41%
30.92%
19.92%
16.53%
9.94%
9.44%
4.82%
13.78%
27.92%
24.38%
Fixed Asset Turnover
1.67
1.75
1.65
1.48
1.37
1.43
1.23
1.42
1.89
1.95
Receivable days
53.92
57.48
61.90
62.09
61.27
53.75
50.16
46.12
47.78
49.05
Inventory Days
108.09
98.25
94.05
94.47
97.98
97.70
110.76
101.93
87.49
90.74
Payable days
111.16
136.39
49.85
51.13
50.35
52.23
52.92
39.11
36.45
31.30
Cash Conversion Cycle
50.86
19.34
106.10
105.43
108.90
99.22
108.00
108.95
98.82
108.49
Total Debt/Equity
0.14
0.05
0.13
0.15
0.23
0.29
0.38
0.42
0.31
0.40
Interest Cover
102.40
114.20
38.77
25.65
11.69
11.05
4.38
12.24
21.86
13.45

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • USFDA conducts inspection at Ipca Laboratories’ formulations manufacturing unit at Piparia
    27th Apr 2023, 09:24 AM

    At the conclusion of the inspection, the USFDA issued a Form 483 with 3 observations

    Read More
  • Ipca Laboratories inks pact to acquire 33.4% stake in Unichem Laboratories
    24th Apr 2023, 16:58 PM

    The business and product range of Ipca and that of Unichem complements each others business and product range

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.